Wednesday, July 15, 2009
A PHASE III ALZHEIMER’S DRUG INCREASES LEVELS OF BETA AMYLOID IN THE BRAIN – BUT STILL PROVIDES BENEFITS
- Immunotherapy Targets Alzheimer’s Tau Tangles -
- More Doctors Diagnosing and Treating Mild Cognitive Impairment -
Vienna, July 15, 2009 – Surprising new insights into how a Phase III Alzheimer’s drug might work were among the advances in potential therapies targeting two abnormal brain proteins – beta amyloid and phosphorylated tau – that were reported today at the Alzheimer’s Association 2009 International Conference on Alzheimer’s Disease (ICAD 2009) in Vienna.
Scientists also reported on how clinicians view and treat mild cognitive impairment (MCI), a research category used to define the state between normal aging and Alzheimer’s, that is now being used widely in clinical practice.
“There are now more than 26 million people living with Alzheimer’s and dementia around the world. The cost of caring for these people, and those who will get it in the next few years, will bankrupt the world’s healthcare systems,” said Ralph Nixon, PhD, MD, vice chair of the Alzheimer’s Association Medical & Scientific Advisory Council.
“But, as these studies and many hundreds more reported at ICAD 2009 show, there is hope. There are currently dozens of drugs in clinical trials for Alzheimer’s. This, combined with advancements in diagnostic tools, has the potential to change the landscape of Alzheimer’s in our lifetime. How fast we get there depends completely on the investment in research. We need more government and private dollars for Alzheimer’s research now to capitalize on the progress we’ve made in the last decade,” Nixon added.
The studies reported at ICAD 2009 were:
-- Sam Gandy, et al -- Dimebon®, A Clinically Promising Drug For Alzheimer Disease, Regulates Amyloid-Beta Metabolism In Cultured Cells, In Isolated Nerve Terminals, And In The Interstitial Fluid Of The Living Rodent Brain.
-- Moran Boimel, et al -- Immunotherapy Targeting Pathologically Phosphorylated Tau In A Tauopathy Mouse Model.
-- Scott Roberts, et al -- Clinical Practices Regarding Mild Cognitive Impairment (MCI) Among Neurology Service Providers.
For more information, visit: http://www.alz.org
- More Doctors Diagnosing and Treating Mild Cognitive Impairment -
Vienna, July 15, 2009 – Surprising new insights into how a Phase III Alzheimer’s drug might work were among the advances in potential therapies targeting two abnormal brain proteins – beta amyloid and phosphorylated tau – that were reported today at the Alzheimer’s Association 2009 International Conference on Alzheimer’s Disease (ICAD 2009) in Vienna.
Scientists also reported on how clinicians view and treat mild cognitive impairment (MCI), a research category used to define the state between normal aging and Alzheimer’s, that is now being used widely in clinical practice.
“There are now more than 26 million people living with Alzheimer’s and dementia around the world. The cost of caring for these people, and those who will get it in the next few years, will bankrupt the world’s healthcare systems,” said Ralph Nixon, PhD, MD, vice chair of the Alzheimer’s Association Medical & Scientific Advisory Council.
“But, as these studies and many hundreds more reported at ICAD 2009 show, there is hope. There are currently dozens of drugs in clinical trials for Alzheimer’s. This, combined with advancements in diagnostic tools, has the potential to change the landscape of Alzheimer’s in our lifetime. How fast we get there depends completely on the investment in research. We need more government and private dollars for Alzheimer’s research now to capitalize on the progress we’ve made in the last decade,” Nixon added.
The studies reported at ICAD 2009 were:
-- Sam Gandy, et al -- Dimebon®, A Clinically Promising Drug For Alzheimer Disease, Regulates Amyloid-Beta Metabolism In Cultured Cells, In Isolated Nerve Terminals, And In The Interstitial Fluid Of The Living Rodent Brain.
-- Moran Boimel, et al -- Immunotherapy Targeting Pathologically Phosphorylated Tau In A Tauopathy Mouse Model.
-- Scott Roberts, et al -- Clinical Practices Regarding Mild Cognitive Impairment (MCI) Among Neurology Service Providers.
For more information, visit: http://www.alz.org
posted by Action Alz @ 3:00 PM
1 Comments
|
1 Comments:
My daughter works with Radiant Research in Santa Rosa, Ca and the trial they are using seems to be great. It is an antihistamine. I tried to get my mom in the research program here in SC, but because of a small benign tumor on the front lobal of her brain, she was excluded from the study. She is in her 3rd week of Namenda and while her memory is still still...the namenda has taken away the empty gaze and has returned laughter to her life. I am hopeful.
Post a Comment
Subscribe to Post Comments [Atom]
<< Home